Testosterone Treatment Improves Insulin Resistance in Japanese Male Metabolic Syndrome

A testosterone enanthate (Enarmon Depot Intramuscular Injection 250 mg, every 2 weeks) was administered to the subjects. Before and 3 to 6 months after administration of the testosterone enanthate, BMI, waist circumference, fasting plasma glucose (FPG), fasting plasma immunoreactive insulin (F-IRI), HbA1c, homeostasis model assessment ratio (HOMA-R), total cholesterol (TCHO), triglyceride (TG), HDL-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), free testosterone (Free-Testo), luteinizing hormone(LH), and follicle-stimulating hormone(FSH) were measured and the changes in these parameters were compared. HOMA-R was calculated from FPG and F-IRI values: HOMA-R=FPG (mg/dL)F-IRI (U/mL]/405. The results are displayed as mean SD. Student's t-test was employed, and a difference was considered to be statistically significant when the hazard ratio was less than 5%.